MiMedx Group Inc Common Stock (MDXG)
Stock · NASDAQ · Health Care
$4.43as of 10/16/2026
Price chart
Active signals
MDXG Signal Track Record
How signals performed across all stocks →What MDXG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -1.7% | 40% | September 10, 2026 |
| Bollinger Band Breakout | 24 | -0.6% | 42% | September 22, 2026 |
| Bollinger Band BreakdownActive now | 20 | +0.2% | 50% | April 16, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -6.9% | 15% | September 8, 2026 |
| Any 20-session window (baseline) | -0.8% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 808
- Website
- mimedx.com/
Fundamentals
- 1-day range
- $4.46$4.66
- Market cap
- $609.28M
- P/E (trailing)
- 109.34
- P/E (forward)
- 32.82
- EPS (trailing)
- $0.04
- Dividend yield
- —
- Beta
- 1.20
- Avg. volume
- 1.22M
How MiMedx Group Inc Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
MiMedx Group Inc Common Stock Competitors
Chosen by industry and closest market cap.
- MDXGMiMedx Group Inc Common Stock$4.43▼ 5.34%Market cap $609.28MP/E 109.34$3.03$7.97
- ANGOAngioDynamics Inc. Common Stock$11.24▼ 2.94%Market cap $624.53MP/E —$9.39$16.29
- BWAYBrainsWay Ltd. American Depositary Shares$11.44▼ 3.21%Market cap $626.52MP/E 53.55$2,391$5,123
- BBNXBeta Bionics Inc. Common Stock$16.35▼ 5.55%Market cap $634.80MP/E —$8.8$32.71
- TCMDTactile Systems Technology Inc. Common Stock$22.52▼ 3.31%Market cap $650.97MP/E 21.02$14.43$37.77
- KIDSOrthoPediatrics Corp. Common Stock$21.95▼ 2.75%Market cap $549.03MP/E —$14.42$26.74
- DCTHDelcath Systems Inc. Common Stock$14.08▼ 4.93%Market cap $534.05MP/E 962.21$8.12$17.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MDXG MiMedx Group Inc Common Stock | $609.28M | 109.34 | $4.43 | ▼ 5.34% | $3.03$7.97 |
| ANGO AngioDynamics Inc. Common Stock | $624.53M | — | $11.24 | ▼ 2.94% | $9.39$16.29 |
| BWAY BrainsWay Ltd. American Depositary Shares | $626.52M | 53.55 | $11.44 | ▼ 3.21% | $2,391$5,123 |
| BBNX Beta Bionics Inc. Common Stock | $634.80M | — | $16.35 | ▼ 5.55% | $8.8$32.71 |
| TCMD Tactile Systems Technology Inc. Common Stock | $650.97M | 21.02 | $22.52 | ▼ 3.31% | $14.43$37.77 |
| KIDS OrthoPediatrics Corp. Common Stock | $549.03M | — | $21.95 | ▼ 2.75% | $14.42$26.74 |
| DCTH Delcath Systems Inc. Common Stock | $534.05M | 962.21 | $14.08 | ▼ 4.93% | $8.12$17.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- MiMedx, Sanara Receive U.S. Federal Trading Commission Second Request For Additional Information, Documentary Materials For Proposed Business Combinationbenzinga · 10/16/2026
- MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification MatterYahoo · 9/23/2026
- MiMedx Group Announces U.S. Court Issues Favorable Ruling In Co.'s Litigation Against FDA's Regulatory Classification Of AXIOFILLBenzinga · 9/23/2026
Insider Activity
Insider Actions →- DOUG RICE · July 2, 2026 · Tax Withholding12.7K @ $3.95
- Maersk-Moller Kimberly · June 24, 2026 · Tax Withholding19.8K @ $3.83
- Newton Todd · June 10, 2026 · Grant50.9K @ $3.64
- Tiffany Olson · June 10, 2026 · Grant50.9K @ $3.64
- PUHY DOROTHY E · June 10, 2026 · Grant50.9K @ $3.64
- James L. Bierman · June 10, 2026 · Grant50.9K @ $3.64
- William A. Hawkins · June 10, 2026 · Grant50.9K @ $3.64
Institutional Ownership
March 31, 2026
- Total shares held
- 110.32M
- Total value held
- $428.80M
- Institutional holders
- 230
- Unknown28.20M
- Unknown11.91M
- Unknown7.18M
- Unknown5.17M
- Unknown5.06M
- Unknown3.41M
- Unknown3.40M
- Unknown3.02M
- Unknown2.88M
- Unknown2.84M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification
A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.